247083-08-5

Basic information

• Product Name: 4-bromo-1-trityl-1H-benzimidazole
• Synonyms: 1H-Benzimidazole, 4-bromo-1-(triphenylmethyl)-; 4-Bromo-1-trityl-1H-benzimidazole
• CAS NO: 247083-08-5
• Molecular Formula: C₂₆H₁₉BrN₂
• Molecular Weight: 439.3465
• Mol File: 247083-08-5.mol

Chemical Properties

• Boiling Point: 592.4°C at 760 mmHg
• Flash Point: 312.1°C
• Density: 1.28g/cm³
• Vapor Pressure: 5.27E-14mmHg at 25°C
• Refractive Index: 1.65
• CAS DataBase Reference: 4-bromo-1-trityl-1H-benzimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-1-trityl-1H-benzimidazole(247083-08-5)
• EPA Substance Registry System: 4-bromo-1-trityl-1H-benzimidazole(247083-08-5)

Safety Data

• Hazardous Substances Data: 247083-08-5(Hazardous Substances Data)

Upstream product

• 83741-35-9 4-bromo-1H-benzo[d]imidazole 
• 76-83-5 trityl chloride 

Downstream Products

• 247083-16-5 2-[4-[4-(1-tritylbenzimidazol-4-yl)piperazin-1-yl]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole 
• 51-17-2 benzoimidazole 
• 247083-11-0 1-(1-tritylbenzimidazol-4-yl)-4-methylpiperazine 
• 247083-12-1 4-(piperazin-1-yl)-1-trityl-1H-benzo[d]imidazole 

Relevant articles and documents

COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)

The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity. The compounds of the disclosure include compounds Formula (I).

COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease and/or mitchonodrial disease including Parkinson's disease and Leigh's disease.

Pd(0) amination of benzimidazoles as an efficient method towards new (benzimidazolyl)piperazines with high affinity for the 5-HT(1A) receptor

New (benzimidazolyl)amines have been synthesized from 4- and 6- bromobenzimidazole derivatives via palladium-mediated amination reactions. Among them, (benzimidazol-4(7)-yl)piperazine derivatives have been shown to be a new family of high affinity 5-HT(1A) receptor ligands. (C) 2000 Elsevier Science Ltd.

Synthesis of new (benzimidazolyl)piperazines with affinity for the 5- HT(1A) receptor via Pd(0) amination of bromobenzimidazoles

The synthesis of a new family of (benzimidazolyl)piperazines has been developed through Pd(0) mediated amination of 4- and 6-bromobenzimidazole derivatives. Preliminary studies showed that some of these compounds are potent 5-HT(1A) receptor ligands.